Key Points
- Esperion Therapeutics CFO Benjamin Halladay sold 10,773 shares on June 17 at an average price of $3.15, totaling about $33,935. After the sale, he still owned 702,829 shares, a 1.51% reduction in his position.
- ESPR shares were down slightly, opening at $3.15 and trading 0.6% lower. The stock has ranged from $0.95 to $4.18 over the past year and has a market cap of about $811.7 million.
- Recent fundamentals and analyst sentiment remain mixed: the company missed Q1 earnings and revenue estimates, and the stock currently has a Hold consensus rating with an average price target of $5.54 after several analyst downgrades.
Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) CFO Benjamin Halladay sold 10,773 shares of the firm's stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $3.15, for a total transaction of $33,934.95. Following the completion of the sale, the chief financial officer directly owned 702,829 shares in the company, valued at approximately $2,213,911.35. This trade represents a 1.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Esperion Therapeutics Trading Down 0.6%
Shares of ESPR opened at $3.15 on Friday. Esperion Therapeutics, Inc. has a twelve month low of $0.95 and a twelve month high of $4.18. The firm's fifty day simple moving average is $2.76 and its 200-day simple moving average is $3.11. The firm has a market capitalization of $811.72 million, a price-to-earnings ratio of -52.50 and a beta of 1.07.
Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.08). The firm had revenue of $80.10 million for the quarter, compared to analyst estimates of $84.52 million. Esperion Therapeutics had a negative return on equity of 0.14% and a net margin of 0.12%.
Hedge Funds Weigh In On Esperion Therapeutics
Several hedge funds have recently made changes to their positions in ESPR. ADAR1 Capital Management LLC purchased a new stake in shares of Esperion Therapeutics in the 1st quarter valued at about $59,000. Excelsior Advisor Network LLC purchased a new position in Esperion Therapeutics during the 1st quarter worth approximately $123,000. Lazard Asset Management LLC grew its stake in Esperion Therapeutics by 1,621.1% during the 1st quarter. Lazard Asset Management LLC now owns 580,705 shares of the biopharmaceutical company's stock worth $1,591,000 after buying an additional 546,964 shares during the last quarter. Orbimed Advisors LLC grew its stake in Esperion Therapeutics by 77.2% during the 1st quarter. Orbimed Advisors LLC now owns 10,570,300 shares of the biopharmaceutical company's stock worth $28,963,000 after buying an additional 4,604,802 shares during the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new position in Esperion Therapeutics during the first quarter worth approximately $1,428,000. Hedge funds and other institutional investors own 47.39% of the company's stock.
Analysts Set New Price Targets
ESPR has been the topic of several research analyst reports. Jefferies Financial Group lowered Esperion Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 1st. Piper Sandler downgraded Esperion Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, May 1st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Esperion Therapeutics in a research note on Tuesday, April 21st. Citizens Jmp cut shares of Esperion Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, May 1st. Finally, HC Wainwright downgraded shares of Esperion Therapeutics from a "buy" rating to a "neutral" rating and set a $3.16 price objective for the company. in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Esperion Therapeutics presently has a consensus rating of "Hold" and an average target price of $5.54.
Check Out Our Latest Stock Analysis on ESPR
Esperion Therapeutics Company Profile
(
Get Free Report)
Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company's research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.
The company's lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
